Chat with us
Research Assistance
Online
  • Please enter your first name.

South Korea Alzheimers Therapeutics Market Size & Outlook

The alzheimers therapeutics market in South Korea is expected to reach a projected revenue of US$ 2,398.1 million by 2033. A compound annual growth rate of 15.4% is expected of South Korea alzheimers therapeutics market from 2026 to 2033.

  • Pharmaceuticals
    • Neurology Drugs
      • Alzheimers Therapeutics Market Outlook
Revenue, 2025 (US$M)
$653.8
Forecast, 2033 (US$M)
$2,398.1
CAGR, 2026 - 2033
15.4%
Report Coverage
South Korea

South Korea Alzheimers Therapeutics Market, 2021-2033 (US$M)

South Korea Alzheimers Therapeutics Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Prism AI by Grand View ResearchFree to try

Ask a question about the alzheimers therapeutics market

Every figure cited from GVR research

South Korea alzheimers therapeutics market outlook highlights

The South Korea alzheimers therapeutics market outlook generated a revenue of USD 653.8 million in 2025 and is expected to reach USD 2,398.1 million by 2033.
  • The market is expected to grow at a CAGR of 15.4% from 2026 to 2033.
  • In terms of segment, cholinesterase inhibitors was the largest revenue generating drug class in 2025.
  • Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.

  • Alzheimers Therapeutics Market Outlook data book summary

    Market revenue in 2025USD 653.8 million
    Market revenue in 2033USD 2,398.1 million
    Growth rate15.4% (CAGR from 2026 to 2033)
    Largest segmentCholinesterase Inhibitors
    Fastest growing segmentMonoclonal Antibodies
    Historical data2021 - 2024
    Base year2025
    Forecast period2026 - 2033
    Quantitative unitsRevenue in USD million
    Market segmentationCholinesterase Inhibitors, Nmda Receptor Antagonist, Combination Drugs, Monoclonal Antibodies
    Key market players worldwideEisai Co Ltd, Novartis Ag Adr, Abbvie Inc, H. Lundbeck As Class A, Biogen Inc, Roche Holding Ag Adr, Daiichi Sankyo Co Ltd, Johnson & Johnson, Ac Immune Sa

    Other key industry trends

      In terms of revenue, South Korea accounted for 2.8% of the global alzheimers therapeutics market outlook in 2025.
    • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
    • In Asia Pacific, China alzheimers therapeutics market outlook is projected to lead the regional market in terms of revenue in 2033.

    No credit card required*

    Publish Date: Sep 02, 2026

    Customize the Report

    20% free customization

    Include
    Countries, segments, points
    Tailor
    To your product definition
    Extend
    Deeper competitor detail
    Or
    A fully bespoke study

    Horizon in a snapshot

    • 30K+ Global Market Reports
    • 120K+ Country Reports
    • 1.2M+ Market Statistics
    • 200K+ Company Profiles
    • Industry insights and more

    Alzheimers Therapeutics Market Companies

    NameProfile# EmployeesHQWebsite
    Johnson & JohnsonView profile 134,400One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933www.jnj.com
    Novartis AG ADRView profile 76,057Lichtstrasse 35, Basel, Switzerland, 4056www.novartis.com
    Roche Holding AG ADRView profile 103,605Grenzacherstrasse 124, Basel, Switzerland, 4070www.roche.com
    AbbVie IncView profile 50,0001 North Waukegan Road, North Chicago, IL, United States, 60064-6400www.abbvieinvestor.com
    Biogen IncView profile 7,570225 Binney Street, Cambridge, MA, United States, 02142www.biogen.com
    Daiichi Sankyo Co LtdView profile 17,4353-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426www.daiichisankyo.com
    Eisai Co LtdView profile 11,0764-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088www.eisai.co.jp
    H. Lundbeck AS Class AView profile 5,700Ottiliavej 9, Valby, Denmark, 2500www.lundbeck.com
    AC Immune SAView profile 161EPFL Innovation Park, Building B, Lausanne, Switzerland, 1015www.acimmune.com

    South Korea Alzheimers Therapeutics Market Outlook

    The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Alzheimers Therapeutics Market Outlook will help companies and investors design strategic landscapes.


    Cholinesterase Inhibitors was the largest segment with a revenue share of 52.03% in 2025.

    Horizon Databook has segmented the South Korea alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs, monoclonal antibodies covering the revenue growth of each sub-segment from 2021 to 2033.


    • South Korea Alzheimers Therapeutics Market Drug Class Outlook (Revenue, USD million , 2021-2033)
      • Cholinesterase inhibitors
      • NMDA Receptor Antagonist
      • Combination Drugs
      • Monoclonal Antibodies
    • South Korea Alzheimers Therapeutics Market End User Outlook (Revenue, USD million , 2021-2033)
      • Hospital Pharmacy
      • Retail Pharmacy
      • E-commerce

    Reasons to subscribe to Alzheimers Therapeutics Market Outlook databook

    • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
    • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
    • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
    • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
    • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

    Target buyers of Alzheimers Therapeutics Market Outlook databook

    • Our clientele includes a mix of Alzheimers Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
    • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
    • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
    • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

    Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Alzheimers Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Alzheimers Therapeutics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

    South Korea Alzheimers Therapeutics Market, 2021-2033 (US$M)

    No Access Stack Chart

    South korea alzheimers therapeutics market statistics, by drug class 2021 - 2033 (US$M)

    No Access Pie Chart

    South korea alzheimers therapeutics market statistics, by drug class 2021 - 2033 (USD million)

    No Access

    Sign up - it's easy, and free!

    Sign up and get instant basic access to databook, upgrade
    when ready, or enjoy our free plan indefinitely.

    Included in Horizon account

    • 30K+ Global Market Reports
    • 120K+ Country Reports
    • 1.2M+ Market Statistics
    • 200K+ Company Profiles
    • Industry insights and more